[Therapeutic results and pharmacokinetics of combined used anticancer drug in intraperitoneal hyperthermo-chemotherapy (CHPP)].

Continuous hyperthermic peritoneal perfusion (CHPP) was performed after curative gastrectomy for the patients with serosally invading gastric cancer to control their peritoneal recurrence. In the randomized control study of this prophylactic CHPP, using 10 l of physiological saline with 100 mg of mitomycin C or 150 mg of cisplatin (CDDP) at 42 degrees C, better post-operative survival was obtained in the CHPP group than the control group, two-year survivals were 83% in the CHPP and 70% in the control. Through the evaluation of time-concentration curve of free-Pt in serum, the side effects of CDDP in the CHPP treatment were considered to be almost equal to that of 25 mg of CDDP in the intravenous injection. In the experiments using rats, the concentration of Pt in the peritoneal tissue after CHPP was three times higher than that after intravenous injection of 2 mg of CDDP. These three results, better survival, less side effects and higher drug concentration of the peritoneal tissue, support the reasonableness of CHPP.